The Australian Diabetes Society (ADS) develops diabetes related clinical guidelines and position statements from working parties consisting of endocrinologists, diabetes educators, general practitioners and other healthcare professionals providing their clinical expertise. The ADS established the Clinical Standards/Guidelines Advisory Committee (CAC) where the members review and provide feedback on guidelines, positions statements and consultation requests. The ADS also engages and in collaboration with other key stakeholder organisations for their professional advice on relevant publications. Endorsement by the Australian Diabetes Society and use of the ADS logo on any such publication requires that the ADS be invited and involved in the development of that particular position statement or clinical guideline.
Search results appear below the blue box
Summary Developed by an expert working group of representatives from the Australian Diabetes Society (ADS), Australian Diabetes Educators Association (ADEA), Royal Australian College of General Practitioners (RACGP) and Dietitians Australia,
Summary A joint guideline by the Australian Diabetes Society (ADS) and Australian and New Zealand Society of Nuclear Medicine (ANZSNM) for PET/CT imaging in patients with type 1 and type
Australian Obesity Management Algorithm SummaryObesity is a complex and multi-factorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. In 2014-15, 63.4% of Australians aged 18
Summary A consensus clinical practice recommendation endorsed by the Australian Diabetes Society (ADS), National Association of Clinical Obesity Services (NACOS), Gastroenterological Society of Australia (GESA) and Australian and New Zealand
Summary The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer
Summary Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus Position Statement The use of glycated haemoglobin (HbA1c) for diagnosis of diabetes mellitus has been
Summary The ADS together with ADEA and ANZCA have made an update to the Alert – ‘Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor use in People with Diabetes’ incorporating recently published
ADS Position Statement ‘Medical Certification of Persons with Insulin-treated Diabetes in the Aviation Industry’ This is the first ADS supported position statement to address medical certification of diabetes in
The prevalence of diabetes is rising and so too is the complexity of diabetes management. There is an increasing number of diabetes medication classes and of medications within each of
Optimal initial medication We suggest the use of metformin as first-line monotherapy in adults with type 2 diabetes. Optimal Add-On Medication We recommend the addition of an SGLT-2 inhibitor to
For all enquiries:
145 Macquarie Street,
Sydney, NSW, 2000
Acknowledgement of Country
The Australian Diabetes Society acknowledges the Traditional Custodians of the lands upon which we live, learn and work.
We pay our respects to Elders both past, present and future.
Design by Aptly
